What is Cardiff Oncology Inc?
, a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 66.34M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 0 | 4776,352 shares $1.1M |
| 6-9months | 0 | 0 |
| 9-12months | 0 | 0 |